STOPDAPT-3研究对有或无糖尿病患者在择期或急诊冠状动脉介入治疗后使用普拉格雷单药治疗的亚组分析：我们为此做好准备了吗？ - Suppr

Suppr

超能文献

STOPDAPT-3 subanalysis on prasugrel monotherapy after elective or emergent coronary intervention in patients with or without diabetes: are we ready for this?

作者信息

Kang Jeehoon, Gargiulo Giuseppe

机构信息

Cardiovascular Center, Seoul National University Hospital, 101 Deahakro, Chongno-gu, Seoul 03080, Republic of Korea.

Department of Advanced Biomedical Sciences, Federico II University of Naples, Via Pansini 5, 80131, Naples, Italy.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):45-47. doi: 10.1093/ehjcvp/pvae079.

DOI:10.1093/ehjcvp/pvae079

PMID:39558848

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11805681/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceb9/11805681/5e895fea655c/pvae079fig1.jpg

相似文献

STOPDAPT-3 subanalysis on prasugrel monotherapy after elective or emergent coronary intervention in patients with or without diabetes: are we ready for this?

Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):45-47. doi: 10.1093/ehjcvp/pvae079.

Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial.

Eur Heart J. 2024 Dec 16;45(47):5042-5054. doi: 10.1093/eurheartj/ehae617.

Clopidogrel Monotherapy vs. Aspirin Monotherapy Following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation.

Circ J. 2020 Aug 25;84(9):1483-1492. doi: 10.1253/circj.CJ-20-0298. Epub 2020 Jul 18.

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.

JACC Cardiovasc Interv. 2023 Jan 9;16(1):19-31. doi: 10.1016/j.jcin.2022.09.053. Epub 2022 Dec 14.

An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial.

Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):34-44. doi: 10.1093/ehjcvp/pvae075.

Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial.

Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):198-209. doi: 10.1093/ehjcvp/pvaf002.

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.

Circ Cardiovasc Interv. 2022 Aug;15(8):e012004. doi: 10.1161/CIRCINTERVENTIONS.122.012004. Epub 2022 Aug 1.

Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.

Cardiovasc Interv Ther. 2021 Oct;36(4):403-415. doi: 10.1007/s12928-020-00719-6. Epub 2020 Nov 12.

An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.

Circulation. 2024 Feb 20;149(8):585-600. doi: 10.1161/CIRCULATIONAHA.123.066720. Epub 2023 Nov 23.

Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 Trial.

J Am Heart Assoc. 2024 Aug 6;13(15):e034201. doi: 10.1161/JAHA.123.034201. Epub 2024 Jul 26.

引用本文的文献

Lipid treatment.

Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):105-106. doi: 10.1093/ehjcvp/pvaf009.

本文引用的文献

An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial.

Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):34-44. doi: 10.1093/ehjcvp/pvae075.

2024 ESC Guidelines for the management of chronic coronary syndromes.

Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177.

An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.

Circulation. 2024 Feb 20;149(8):585-600. doi: 10.1161/CIRCULATIONAHA.123.066720. Epub 2023 Nov 23.

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

Eur Heart J. 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192.

Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.

J Thromb Thrombolysis. 2022 Oct;54(3):461-469. doi: 10.1007/s11239-022-02696-4. Epub 2022 Sep 1.

Coronary In-Stent Restenosis: JACC State-of-the-Art Review.

J Am Coll Cardiol. 2022 Jul 26;80(4):348-372. doi: 10.1016/j.jacc.2022.05.017.

Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.

Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):707-716. doi: 10.1093/ehjcvp/pvac016.

Diabetes mellitus is independently associated with early stent thrombosis in patients undergoing drug eluting stent implantation: Analysis from the Victorian cardiac outcomes registry.

Catheter Cardiovasc Interv. 2022 Feb;99(3):554-562. doi: 10.1002/ccd.29913. Epub 2021 Aug 14.

Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus.

Circulation. 2020 Dec;142(22):2172-2188. doi: 10.1161/CIRCULATIONAHA.120.045465. Epub 2020 Nov 30.

State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives.

EuroIntervention. 2017 Aug 25;13(6):717-733. doi: 10.4244/EIJ-D-17-00468.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

STOPDAPT-3 subanalysis on prasugrel monotherapy after elective or emergent coronary intervention in patients with or without diabetes: are we ready for this?

作者信息

Kang Jeehoon, Gargiulo Giuseppe

机构信息

Cardiovascular Center, Seoul National University Hospital, 101 Deahakro, Chongno-gu, Seoul 03080, Republic of Korea.

Department of Advanced Biomedical Sciences, Federico II University of Naples, Via Pansini 5, 80131, Naples, Italy.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):45-47. doi: 10.1093/ehjcvp/pvae079.

DOI:10.1093/ehjcvp/pvae079

PMID:39558848

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11805681/

Abstract

摘要

相似文献

STOPDAPT-3 subanalysis on prasugrel monotherapy after elective or emergent coronary intervention in patients with or without diabetes: are we ready for this?

Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):45-47. doi: 10.1093/ehjcvp/pvae079.

Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial.

Eur Heart J. 2024 Dec 16;45(47):5042-5054. doi: 10.1093/eurheartj/ehae617.

Clopidogrel Monotherapy vs. Aspirin Monotherapy Following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation.

Circ J. 2020 Aug 25;84(9):1483-1492. doi: 10.1253/circj.CJ-20-0298. Epub 2020 Jul 18.

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.

JACC Cardiovasc Interv. 2023 Jan 9;16(1):19-31. doi: 10.1016/j.jcin.2022.09.053. Epub 2022 Dec 14.

An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial.

Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):34-44. doi: 10.1093/ehjcvp/pvae075.

Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial.

Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):198-209. doi: 10.1093/ehjcvp/pvaf002.

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.

Circ Cardiovasc Interv. 2022 Aug;15(8):e012004. doi: 10.1161/CIRCINTERVENTIONS.122.012004. Epub 2022 Aug 1.

Cardiovasc Interv Ther. 2021 Oct;36(4):403-415. doi: 10.1007/s12928-020-00719-6. Epub 2020 Nov 12.

An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.

Circulation. 2024 Feb 20;149(8):585-600. doi: 10.1161/CIRCULATIONAHA.123.066720. Epub 2023 Nov 23.

Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 Trial.

J Am Heart Assoc. 2024 Aug 6;13(15):e034201. doi: 10.1161/JAHA.123.034201. Epub 2024 Jul 26.

引用本文的文献

Lipid treatment.

Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):105-106. doi: 10.1093/ehjcvp/pvaf009.

本文引用的文献

An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial.

Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):34-44. doi: 10.1093/ehjcvp/pvae075.

2024 ESC Guidelines for the management of chronic coronary syndromes.

Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177.

An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.

Circulation. 2024 Feb 20;149(8):585-600. doi: 10.1161/CIRCULATIONAHA.123.066720. Epub 2023 Nov 23.

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

Eur Heart J. 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192.

Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.

J Thromb Thrombolysis. 2022 Oct;54(3):461-469. doi: 10.1007/s11239-022-02696-4. Epub 2022 Sep 1.

Coronary In-Stent Restenosis: JACC State-of-the-Art Review.

J Am Coll Cardiol. 2022 Jul 26;80(4):348-372. doi: 10.1016/j.jacc.2022.05.017.

Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.

Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):707-716. doi: 10.1093/ehjcvp/pvac016.

Diabetes mellitus is independently associated with early stent thrombosis in patients undergoing drug eluting stent implantation: Analysis from the Victorian cardiac outcomes registry.

Catheter Cardiovasc Interv. 2022 Feb;99(3):554-562. doi: 10.1002/ccd.29913. Epub 2021 Aug 14.

Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus.

Circulation. 2020 Dec;142(22):2172-2188. doi: 10.1161/CIRCULATIONAHA.120.045465. Epub 2020 Nov 30.

State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives.

EuroIntervention. 2017 Aug 25;13(6):717-733. doi: 10.4244/EIJ-D-17-00468.